ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Liraglutide

Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.

Drug pageLiraglutide: every studyMany companies study it; this page follows only the 109 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 22, 2013109 company-led studies, 5 open or runningNext primary completion: Dec 13, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk972 open or runningphase 4since Jul 22, 2013Sep 8, 2005Dec 13, 2026phase 1 · NCT07225816
4Moving Biotechits history only20 open or runningphase 2since Sep 24, 2025Jun 7, 2022none ahead
Eli Lillyits history only20 open or runningphase 4since Feb 24, 2014May 31, 2013none ahead
Tonghua Dongbao Pharmaceuticalits history only22 open or runningphase 3since Aug 14, 2024Jun 2, 2024none ahead
Biolingusits history only11 open or runningphase 2since Feb 16, 2022Feb 16, 2022none ahead
Cinnagenits history only10 open or runningphase 3since Jan 29, 2018Jan 29, 2018none ahead
ikfe-CROits history only10 open or runningphase 4since Sep 17, 2010Sep 17, 2010none ahead
Merckits history only10 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Pfizerits history only10 open or runningphase 1since Feb 1, 2017Feb 1, 2017none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 1since Aug 24, 2021Aug 24, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Jan 6, 2012.

  1. May 11, 2015Phase 2 study in Diabetes MellitusNCT02443155 · 308 enrolled · United States, Austria, Belgium and more
  2. Jul 15, 20152 phase 3 studies in Diabetes MellitusNCT02501161, NCT02505334
  3. Aug 17, 2015Phase 3 study in Nutrition DisordersNCT02527200 · 56 enrolled · United States, Australia, Canada and more
  4. Nov 16, 2015Phase 3 study in Diabetes MellitusNCT02607306 · 819 enrolled · Japan
  5. Feb 26, 2016Phase 1 study in Nutrition DisordersNCT02696148 · 24 enrolled · United States
  6. Mar 15, 2016Phase 1 study in Nutrition DisordersNCT02717858 · 52 enrolled · Denmark
  7. Mar 23, 2016Phase 4 study in Diabetes MellitusNCT02730377 · 1,991 enrolled · United States, Canada, Colombia and more
  8. May 13, 2016Phase 3 study in Diabetes MellitusNCT02773368 · 420 enrolled · United States, Argentina, Canada and more
  9. Sep 20, 20162 phase 3 studiesNCT02911948, NCT02918279
  10. Nov 10, 20163 phase 3 studiesNCT02963935, NCT02963922, NCT02964247
  11. May 24, 20172 phase 3 studies in Diabetes MellitusNCT03175120, NCT03172494
  12. Sep 19, 2017Phase 1 study in Diabetes MellitusNCT03292185 · 24 enrolled · China
  13. Feb 26, 2021Phase 3 study in ObesityNCT04775082 · 82 enrolled · United States, Belgium, India and more
  14. Nov 5, 2025Phase 1 study in ObesityNCT07225816 · 71 planned · United States

Ahead

  1. Dec 13, 2026Primary completion: phase 1 study in ObesityNCT07225816

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

The newest 60 of 97 Novo Nordisk leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07225816Obesity · United States1RecruitingDec 13, 202671
NCT04775082Obesity · United States, Belgium, India and more3Active, not recruitingAug 1, 202382
NCT03292185Diabetes Mellitus · China1CompletedJan 2, 201824
NCT03175120Diabetes Mellitus · China, Hong Kong3CompletedMar 5, 2019453
NCT03172494Diabetes Mellitus · China3CompletedJun 14, 2019720
NCT02964247Diabetes Mellitus · United States, Brazil, India and more3CompletedMay 4, 2018303
NCT02963935Nutrition Disorders · United States3CompletedMay 23, 2018282
NCT02963922Nutrition Disorders · United States, Canada, Germany and more3CompletedSep 10, 2018396
NCT02918279Nutrition Disorders · United States, Belgium, Mexico and more3CompletedFeb 14, 2019251
NCT02911948Diabetes Mellitus · Japan3CompletedNov 17, 2017210
NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more3CompletedSep 26, 2017420
NCT02730377Diabetes Mellitus · United States, Canada, Colombia and more4CompletedAug 5, 20191,991
NCT02717858Nutrition Disorders · Denmark1CompletedFeb 27, 201752
NCT02696148Nutrition Disorders · United States1CompletedApr 13, 201724
NCT02607306Diabetes Mellitus · Japan3CompletedDec 15, 2017819
NCT02527200Nutrition Disorders · United States, Australia, Canada and more3CompletedNov 4, 202056
NCT02505334Diabetes Mellitus · Japan3CompletedMay 2, 2017635
NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more3CompletedOct 3, 20181,012
NCT02443155Diabetes Mellitus · United States, Austria, Belgium and more2CompletedAug 31, 2018308
NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more3CompletedOct 5, 2016506
NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more3CompletedDec 23, 2015420
NCT02207348Nutrition Disorders · Germany1CompletedSep 201424
NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more3CompletedApr 201531
NCT02098395Diabetes Mellitus · United States, Austria, Belgium and more3CompletedApr 2015835
NCT02008682Diabetes Mellitus · China4CompletedNov 2014368
NCT01973231Diabetes Mellitus · Czech Republic, Finland, France and more4CompletedNov 2014404
NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNov 4, 2014557
NCT01916174Diabetes Mellitus · Germany1CompletedNov 201350
NCT01917656Diabetes Mellitus · Algeria, India, Israel and more4CompletedSep 1, 2014343
NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more4CompletedJun 15, 2015407
NCT01836523Diabetes Mellitus · United States, Argentina, Australia and more3CompletedJun 20151,398
NCT01789086Nutrition Disorders · Germany1CompletedMay 201421
NCT01620489Diabetes Mellitus · United States, France, Poland and more3CompletedAug 20, 2013279
NCT01620476Diabetes Mellitus · Japan1CompletedMar 200424
NCT01620463Diabetes Mellitus · Japan1CompletedMar 200332
NCT01617434Diabetes Mellitus · United States, Argentina, Canada and more3CompletedOct 2013451
NCT01615978Diabetes Mellitus · Japan1CompletedMar 200415
NCT01572740Diabetes Mellitus · Japan3CompletedNov 1, 2012257
NCT01557166Nutrition Disorders · United States, Canada3CompletedJun 1, 2013359
NCT01541215Diabetes Mellitus · United States, Australia, Austria and more3CompletedNov 15, 2017135
NCT01536665Diabetes Mellitus · Austria1CompletedAug 201245
NCT01517568Diabetes Mellitus · Netherlands1CompletedDec 20067
NCT01517555Diabetes Mellitus · Germany1CompletedMay 200718
NCT01516255Diabetes Mellitus · United States1CompletedNov 200664
NCT01515592Diabetes Mellitus · Japan1CompletedApr 200624
NCT01515579Diabetes Mellitus · Sweden1CompletedJun 200622
NCT01515553Diabetes Mellitus · Sweden1CompletedApr 200722
NCT01518166Diabetes Mellitus · Sweden1CompletedApr 200770
NCT01514487Diabetes Mellitus · Australia1CompletedMar 30, 200524
NCT01513525Diabetes Mellitus · Germany1CompletedMay 200721
NCT01511692Diabetes Mellitus · Australia, Germany1CompletedSep 200743
NCT01511198Diabetes Mellitus · United States2CompletedOct 2001223
NCT01511185Diabetes Mellitus · United States1CompletedOct 200120
NCT01511172Diabetes Mellitus · Australia, Austria, Czech Republic and more2CompletedDec 2002145
NCT01511159Diabetes Mellitus · United Kingdom1CompletedDec 200132
NCT01512108Diabetes Mellitus · Japan3CompletedApr 26, 2013363
NCT01508949Diabetes Mellitus · Denmark2CompletedMar 200235
NCT01508923Diabetes Mellitus · Denmark2CompletedFeb 200217
NCT01509755Diabetes Mellitus · Denmark, Norway, Sweden and more2CompletedOct 2001196
NCT01509742Diabetes Mellitus · Germany1CompletedNov 200119

How it is read

Names in the registry

  • “liraglutide”, 114 entries
  • “insulin degludec/liraglutide”, 11 entries
  • “Liraglutide”, 10 entries
  • “Insulin degludec/liraglutide”, 3 entries
  • “NN9924 (oral)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.